Spots Global Cancer Trial Database for Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
Official Title: Maintenance of Remission After Discontinuation of Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
Study ID: NCT05149495
Conditions
Interventions
Study Description
Brief Summary: At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg, Strasbourg, , France
Contact Details
Name: Philippe BALTZINGER, MD
Affiliation: Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
